Navigation Links
Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery
Date:12/11/2013

SAN DIEGO, Dec. 11, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced dosing of the first patients in its two Phase 3 trials of OTO-201 for the treatment of pediatric patients with bilateral middle ear effusion requiring tympanostomy tube placement. OTO-201 is Otonomy's proprietary, sustained-exposure otic formulation of the antibiotic ciprofloxacin.

(Logo: http://photos.prnewswire.com/prnh/20130806/MM59802LOGO)

The two identical, prospective, randomized, double-blind, sham-controlled Phase 3 studies are expected to enroll a combined total of approximately 500 subjects, ages 6 months to 12 years old, across 60 trial sites in the United States and Canada. The primary endpoint of the studies is the effectiveness of OTO-201 as measured through day 15 by the cumulative proportion of study treatment failures, which is defined as the presence of otorrhea (drainage) or use of antibiotic rescue medication. Completion of patient enrollment is expected during the second quarter of 2014.

"Following tube placement surgery, we frequently see parents of these very young patients struggle to comply with repeat administration of ear drops which is important to prevent post-operative complications," said pediatric otolaryngologist, Eric A. Mair, M.D., of Charlotte Eye, Ear, Nose & Throat Associates. "The potential to administer a full course of antibiotics with a single dose given during the procedure would be an attractive treatment option for patients, parents and physicians."

Added David A. Weber, Ph.D., president and CEO of Otonomy, "Initiating the two registration studies for OTO-201 is a major step forward for the company, which has worked diligently to advance this program since the successful completion of the Phase 1b trial less than six months ago. We look forward to having top-line data in the middle of next year to continue this rapid pace towards commercialization."

Subjects will receive either OTO-201 or sham injection in both ears during the operation and will be evaluated for the primary endpoint on days 4, 8 and 15 post surgery. A culture of the effusion from each ear will be obtained prior to treatment with OTO-201 or sham injection and at subsequent time points to determine microbiological response. The two Phase 3 studies will also assess the safety and tolerability of OTO-201 in this setting.

Additional information about study protocol and enrollment sites for the study can be found at www.clinicaltrials.gov using the study identifier NCT01949142 or NCT01949155.

About OTO-201
OTO-201 is a proprietary, sustained-exposure formulation of the antibiotic ciprofloxacin that has been designed for administration by ear, nose and throat (ENT) specialists to treat a broad range of otic conditions including chronic otitis media. Preclinical studies have demonstrated that a single dose of OTO-201 provides sustained ciprofloxacin drug concentrations in the middle ear that exceed levels observed with twice-daily dosing of antibiotic ear drops for seven days. The lead indication for OTO-201 is intra-operative treatment of middle ear effusion (fluid) in pediatric patients requiring tympanostomy tube placement surgery. The product successfully completed a Phase 1b trial that demonstrated a statistically significant reduction of treatment failure of more than 60 percent relative to the placebo/sham group (p<0.05) and the therapy appeared to be well tolerated. OTO-201 began Phase 3 testing in December 2013.

About Tympanostomy Tube Placement Surgery 
Approximately one million tube placement procedures are conducted each year in the United States with the vast majority performed in children suffering from recurrent or persistent otitis media, inflammation or infection of the middle ear. Most patients receiving tubes have middle ear effusion at the time of surgery which significantly increases their risk of post-operative complications including otorrhea (drainage) and tube occlusion. A number of clinical studies have demonstrated that administration of topical antibiotics during and immediately following tube placement surgery significantly reduces this risk. No antibiotic product has been approved by the FDA for this use and current treatment relies on parent compliance with multi-day dosing regimens.

About Otonomy
Otonomy is a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has three product candidates in development. OTO-201 is an antibiotic that is in Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Meniere's disease. OTO-311 is an NMDA antagonist in development as a treatment for tinnitus. For more information please visit: www.otonomy.com.

Contact:
Media Inquiries
Canale Communications
Ian Stone
Account Director
619.849.5388
ian@canalecomm.com

Investor Inquiries
Westwicke Partners
Stefan Loren, Ph.D.
Managing Director
443.213.0507
sloren@westwicke.com

Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com


'/>"/>
SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Menieres Disease
2. Otonomy Acquires Assets and Patent Rights for Tinnitus Program
3. Otonomy Completes $45.9 Million Series C Equity Financing
4. S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD
5. CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
6. Summit Yields One-of-a-Kind Opportunity To Reduce Prescription Drug Overdoses
7. CLAAD Warns of Increase in Prescription Drug Overdoses
8. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
9. As Prescription Painkiller Overdoses Mount, Researchers Outline Effective Approaches to Curb Epidemic
10. First Interim Analysis Of NW Bios Phase III GBM Trial Triggered By Reaching Required Number Of "Events"
11. Varian Medical Systems Schedules First Quarter FY2014 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Global Ampoules Market report provides ... applications and industry chain structure. The Ampoules market analysis ... competitive landscape analysis, and major regions, development status. ... ... providing 10 company profiles and 183 tables and figures ...
(Date:3/24/2017)... 2017  Eli Lilly and Company (NYSE: ... $850 million in its U.S. operations in 2017. ... enterprise, including research laboratories, manufacturing sites, and general ... by demand for Lilly products, as well as ... targeting cancer, pain, diabetes and other unmet medical ...
(Date:3/24/2017)... and GENEVA , March ... on World Tuberculosis Day revitalizes efforts to develop sutezolid ... On World Tuberculosis Day, TB Alliance and the ... the clinical development of sutezolid, an antibiotic drug candidate ... pertains to the development of sutezolid in combination with ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, Inc., a ... hazardous and non-hazardous materials announced today the acquisition of privately owned AERC ... four additional processing facilities and a vast array of additional technologies, services, and ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... the military at the same time by providing Prehospital Trauma Life Support (PHTLS) ... is the world’s premier prehospital trauma education developed in cooperation with the American ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Infection,” which will spark a conversation on the current obstacles facing infection prevention ... of completely preventable deaths caused by these infections. , The print component ...
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... scale; from third world countries to hospitals in the United States, it’s a ... conversation on the current obstacles facing infection prevention and offers strategies for the ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Digital Scientists, ... excited to announce the opening of a Greenville, South Carolina location. The ... digital progress in Greenville. , “We’ve been working with South Carolina clients for years ...
Breaking Medicine News(10 mins):